NASDAQ:ALRN - Aileron Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.23 -0.25 (-16.89 %)
(As of 01/21/2019 08:33 AM ET)
Previous Close$1.48
Today's Range$1.19 - $1.48
52-Week Range$0.52 - $9.88
Volume160,146 shs
Average Volume210,510 shs
Market Capitalization$18.14 million
P/E Ratio-0.69
Dividend YieldN/A
Beta2.14
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

Receive ALRN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALRN
CUSIPN/A
Phone617-995-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.25 per share

Profitability

Net Income$-22,600,000.00

Miscellaneous

Employees13
Market Cap$18.14 million
OptionableNot Optionable

Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics Inc (NASDAQ:ALRN) posted its quarterly earnings results on Wednesday, November, 7th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.58) by $0.08. View Aileron Therapeutics' Earnings History.

When is Aileron Therapeutics' next earnings date?

Aileron Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 1st 2019. View Earnings Estimates for Aileron Therapeutics.

Has Aileron Therapeutics been receiving favorable news coverage?

News articles about ALRN stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aileron Therapeutics earned a news sentiment score of 2.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days.

Who are some of Aileron Therapeutics' key competitors?

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the folowing people:
  • Dr. Manuel C. Aivado, Pres, CEO & Director (Age 49)
  • Mr. Donald V. Dougherty CPA, CFA, Sr. VP & CFO (Age 60)
  • Ms. Kira A. Nelson CPA, VP of Fin. & Operations (Age 50)
  • Dr. D. Allen Annis, Sr. VP of Research
  • Dr. Vojislav Vukovic, Chief Medical Officer

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $1.23.

How big of a company is Aileron Therapeutics?

Aileron Therapeutics has a market capitalization of $18.14 million. The company earns $-22,600,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Aileron Therapeutics employs 13 workers across the globe.

What is Aileron Therapeutics' official website?

The official website for Aileron Therapeutics is http://www.aileronrx.com.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]


MarketBeat Community Rating for Aileron Therapeutics (NASDAQ ALRN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  117 (Vote Outperform)
Underperform Votes:  107 (Vote Underperform)
Total Votes:  224
MarketBeat's community ratings are surveys of what our community members think about Aileron Therapeutics and other stocks. Vote "Outperform" if you believe ALRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel